The use of daclizumab, tacrolimus and mycophenolate mofetil in African-American and Hispanic first renal transplant recipients

American Journal of Transplantation

Volumn 3, Issue 8, 2003, Pages 1010-1016

  Ciancio, Gaetano ^a   Burke, George W ^a   Suzart, Kiliana ^a   Mattiazzi, Adela ^a   Vaidya, Anil ^a   Roth, David ^a   Kupin, Warren ^a   Rosen, Anne ^a   Johnson, Nancy ^a   Miller, Joshua ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

African Americans; Hispanics; Induction therapy; Kidney transplants; Mycophenolate mofetil; Racial minorities; Tacrolimus

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; COTRIMOXAZOLE; CREATININE; DACLIZUMAB; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; ETHNIC GROUP; FOLLOW UP; GASTROINTESTINAL TOXICITY; GRAFT REJECTION; GRAFT SURVIVAL; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MINORITY GROUP; ORGAN TRANSPLANTATION; PNEUMOCYSTIS PNEUMONIA; TREATMENT OUTCOME;

ADULT; AFRICAN AMERICANS; AGED; ANTIBODIES, MONOCLONAL; GRAFT REJECTION; HISPANIC AMERICANS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INFECTION; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MIDDLE AGED; MYCOPHENOLIC ACID; SURVIVAL ANALYSIS; TACROLIMUS;

EID: 12444319387     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2003.00181.x     Document Type: Article

References (29)

1. Sollinger HW, for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225-232.
2. Pirsh JD, Miller J, Deierhoi MH, Vicenti F, Filo R. Comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997; 63: 977-983.
3. Neylan JF, for the US Renal Transplant Mycophenolate Mofetil Study Group. Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. Transplantation 1997; 64: 1277-1282.
4. Neylan JF, for the FK506 Kidney Transplant Study Group. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. Transplantation 1998; 65: 515-523.
5. Vincenti F, Kirkman R, Light S et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161-165.
6. Nashan B, Light S, Hardie IR, Lin A, Johson R, for the Daclizumab Double Therapy Study Group. Reduction of acute renal allograft rejection by daclizumab. Transplantation 1999; 67: 110-115.
7. Meier-Kriesche H-U, Kaza H, Palekar SS et al. The effect of daclizumab in a high-risk renal transplant population. Clin Transplant 2000; 14: 509-513.
8. Levey AS, Bosch JP, Breyer Lewis J et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130: 461-470.
9. Opelz G, Engelmann A. Effect of HLA matching in cyclosporine-treated Black kidney transplant recipients. Transplant Proc 1989; 21: 3881-3883.
10. Zhou YC, Cecka JM, Terasaki PI. Effect of race on kidney transplants. In: Terasaki PI, ed. Clinical Transplants 1990. Los Angeles: UCLA Tissue Typing Laboratory; 1990. pp 447-459.
11. Vasquez EM, Benedetti E, Pollak R. Ethnic differences in clinical response to corticosteroid treatment of acute renal allograft rejection. Transplantation 2001; 71: 229-233.
12. Kerman RH, Kimball PM, Van Buren CT, Lewis RM, Kahan BD. Possible contribution of pre-transplant immune responder status to renal allograft survival difference of black versus white recipients. Transplantation 1991; 51: 338-342.
13. Butkus DE, Maydrech EF, Raju SR. Racial differences in the survival of cadaveric renal allografts: overriding effects of HLA matching and socioeconomic factors. N Engl J Med 1992; 327: 840-845.
14. Koyama H, Cecka JM, Terasaki P. Kidney transplants in blacks recipients: HLA matching and other factors affecting long-term graft survival. Transplantation 1994; 57: 1064-1068.
15. Scantlebury V, Gjertson D, Eliasziw M et al. Effect of HLA mismatch in African-Americans. Transplantation 1998; 65: 586-588.
16. Hata Y, Ozawa M, Takemoto SK, Cecka JM. HLA matching. In: Cecka JM, Terasaki PI, eds. Clinical Transplants 1996. Los Angeles: UCLA Tissue Typing Laboratory; 1997. pp 381-396.
17. Butkus DE, Dottes Al, Meydrech EF, Barber WH. Effect of poverty and other socioeconomic variables on renal allograft survival. Transplantation 2001; 72: 261-266.
18. Gaston RS, Hudson SL, Ward M, Jones P, Macon R. Late renal allograft loss: noncompliance masquerading as chronic rejection. Transplant Proc 1999; 31 (4A): 21S-23S.
19. Ojo AO, Port FK, Held PJ et al. Inferior outcome of two-haplotype matched renal transplants in blacks: role of early rejection. Kidney Int 1995; 48: 1592-1599.
20. Vasquez EM, Benedetti E, Pollack R. Late acute rejection in more prevalent among African-American renal allograft recipients and is frequently associated with allograft loss. Transplant Proc 1998; 30: 1173-1175.
21. Milgrom M, Gharagozloo H, Gomez C et al. Results of renal transplantation in Miami analyzed by race. Transplant Proc 1989; 21: 3934-3936.
22. Vincenti F, for the Tacrolimus Kidney Transplant Study Group. Tacrolimus (FK506) in kidney transplantation. Five-year survival results of the U.S. multicenter, randomized, comparative trial. Transplant Proc 2001; 33: 1019-1020.
23. Solliger HW, for the Us Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225-232.
24. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaver transplantation. Transplantation 1996; 61: 1029-1037.
25. European Mycophenolate Mofetil Cooperative Study Group. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. Transplantation 1999; 68: 391-396.
26. Light JA, Kelly JL, Aquino A, Neu L, Denavas L, Williams K. Improving renal transplant outcomes in African Americans with OKT3 induction therapy. Transplant Proc 1993; 25: 2436-2438.
27. Gaston RS, Hudson SL, Deierhoi MH et al. Improved survival of primary cadaveric renal allografts in blacks with quadruple immunosuppression. Transplantation 1992; 53: 103-109.
28. Johnson C, Ahsan N, Gonwa T et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000; 69: 834-841.
29. Miller J, Mendez R, Pirsch JD, Jensik SC. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. Fk506/MMF Dose-Ranging Kidney Transplant Study Group. Transplantation 2000; 69: 875-880.